What is AUPH (AUPH) stock price today?

AUPH (AUPH) is currently trading at $15.00, down 1.19% today.

What is AUPH P/E ratio?

AUPH's P/E ratio is 7.46. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is AUPH return on equity (ROE)?

AUPH's return on equity (ROE) is 49.40%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is AUPH's market cap?

AUPH has a market capitalization of $1.93B.

NASDAQ · Biotechnology

AUPH (AUPH) Stock

$15.00 -1.19% NASDAQ: AUPH Healthcare

Valuation

Metric	Value
Price	$15.00
Market Cap	$1.93B
P/E Ratio	7.46
P/B Ratio	3.42
P/S Ratio	6.56
EPS (TTM)	$0.00
52-Week High	$19.11
52-Week Low	$7.29
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	49.40%
ROA	38.16%
ROCE	18.04%
Gross Margin	37.10%
Operating Margin	37.10%
Net Margin	99.97%
Debt/Equity	0.12
Current Ratio	5.23

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$46.0M	$134.0M	$176.0M	$235.0M	$283.0M
Operating Profit	$-181.0M	$-111.0M	$-92.0M	$-5.0M	$105.0M
Net Profit	$-181.0M	$-108.0M	$-78.0M	$6.0M	$287.0M
EPS	$-1.40	$-0.76	$-0.54	$0.04	$2.07
Op Margin	-396.3%	-83.2%	-52.2%	-2.0%	37.1%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$543.0M	$471.0M	$548.0M	$551.0M	$752.0M
Total Liabilities	$64.0M	$65.0M	$170.0M	$173.0M	$170.0M
Cash	$232.0M	$94.0M	$49.0M	$83.0M	$80.0M
Borrowings	$9.0M	$8.0M	$98.0M	$79.0M	$75.0M

Latest News

Sector Update: Healthcare Stocks Fall Monday Afternoon MT Newswires · Jul 6, 2026 Aurinia Pharmaceuticals Initiates Phase 4 PRESERVE Study in Lupus Nephritis Combination Therapy MT Newswires · Jul 6, 2026 Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis Business Wire · Jul 6, 2026 Aurinia (AUPH) Upgraded to Strong Buy: Here's Why Zacks · Jul 2, 2026 Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now? Insider Monkey · Jun 29, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-158.0M	$-80.0M	$-33.0M	$44.0M	$136.0M
Investing Cash Flow	$-105.0M	$-61.0M	$-7.0M	$39.0M	$-33.0M
Financing Cash Flow	$24.0M	$2.0M	$5.0M	$-37.0M	$-108.0M
Net Cash Flow	$-40.0M	$-138.0M	$-45.0M	$35.0M	$-3.0M
Free Cash Flow	$-159.0M	$-80.0M	$-34.0M	$44.0M	$135.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	17.39
FCF Yield	8.46%
Quick Ratio	5.01
Interest Coverage	26.25
Return 1Y	72.64%
Return 3Y	40.13%
Return 5Y	35.07%

Ownership

Insiders Held7.53%

Institutions Held60.33%

Institutions Float Held65.25%

Institutional Holder	Shares	Report Date
Tang Capital Management, LLC	12,229,500	2026-03-31
Blackrock Inc.	7,845,521	2026-03-31
NEA Management Company, LLC	3,969,834	2026-03-31
Two Sigma Investments, LP	3,428,705	2026-03-31
Arrowstreet Capital, Limited Partnership	3,284,368	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ABCL	$6.93	+6.13%	-5.91	$2.12B	0.00%
BHVN	$14.07	+3.19%	-6.11	$2.12B	0.00%
CLDX	$35.80	+0.63%	-7.84	$2.38B	0.00%
HRMY	$38.24	-1.39%	11.23	$2.21B	0.00%
IMCRImmunocore Holdings plc	$31.95	-3.42%	-85.34	$1.62B	0.00%

About AUPH

AUPH stock trades at $15.00 with a market capitalization of $1.93B. The stock is valued at a price-to-earnings (P/E) ratio of 7.46, price-to-book of 3.42, price-to-sales of 6.56. Over the past 52 weeks the stock has ranged between $7.29 and $19.11, and currently trades 21.5% below its 52-week high.

On profitability, AUPH generates a return on equity (ROE) of 49.40% — well above the market average, a sign of a high-quality business, return on capital employed of 18.04%, an operating margin of 37.10%, a net profit margin of 99.97%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides